Abstract: The Wnt/β-catenin signaling pathway plays a critical role in the pathogenesis and progression of various digestive system cancers, including hepatocellular carcinoma (HCC), colorectal cancer, and gastric cancer. Aberrant activation of this pathway, often modulated by long noncoding RNAs (lncRNAs), drives tumor cell proliferation, invasion, and the maintenance of cancer stem cells (CSCs). XAV-939 is a targeted small-molecule inhibitor of the Wnt/β-catenin pathway that has demonstrated significant preclinical efficacy. Specifically, in liver cancer models, XAV-939 effectively impairs the self-renewal capabilities of cancer stem cells by reducing spheroid formation. While current research highlights its strong therapeutic potential in oncology, further clinical validation is required to translate these preclinical findings into effective treatments for patients with digestive system malignancies.
1. Introduction
Digestive system cancers, encompassing esophageal, gastric, liver, colorectal, and pancreatic cancers, represent a major global health burden characterized by high incidence and mortality rates [1]. A hallmark of many of these malignancies is the dysregulation of the Wingless (Wnt)/β-catenin signaling pathway, which is crucial for regulating cell proliferation, differentiation, and survival [1]. Mutations in key pathway components or epigenetic alterations often lead to the constitutive activation of Wnt signaling, resulting in uncontrolled cellular proliferation, epithelial-mesenchymal transition (EMT), and tumor metastasis [1]. Recently, the interaction between the Wnt pathway and long noncoding RNAs (lncRNAs) has been identified as a significant driver of cancer progression and chemoresistance [1]. In this context, Wnt pathway inhibitors like XAV-939 have emerged as promising therapeutic agents. XAV-939 has demonstrated preclinical efficacy in counteracting the oncogenic effects of aberrant Wnt signaling, underscoring its potential as a targeted therapy for digestive system tumors [1].
2. Pharmacological Activity
The pharmacological activity of XAV-939 is primarily characterized by its ability to suppress cancer stem cell (CSC) properties in digestive system tumors, particularly hepatocellular carcinoma (HCC) [1]. Cancer stem cells are a subpopulation of tumor cells responsible for tumor initiation, progression, and recurrence. In preclinical models of liver cancer, treatment with XAV-939 significantly impairs the self-renewal capacity of these cells. Specifically, the administration of XAV-939 reduces both the ability of liver CSCs to form spheroids and the total number of spheroids formed [1]. This demonstrates that XAV-939 possesses potent anti-tumorigenic activity by directly targeting the stemness and self-renewal mechanisms that drive liver cancer progression [1].
3. Molecular Mechanism of Action
XAV-939 functions as a targeted inhibitor of the Wnt/β-catenin signaling pathway [1]. In the canonical Wnt pathway, the absence of Wnt ligands allows a destruction complex (including GSK3β and Axin) to phosphorylate β-catenin, marking it for degradation and keeping its cytoplasmic levels low [1]. When aberrantly activated—often through mutations or the influence of oncogenic lncRNAs—β-catenin escapes degradation, accumulates in the cytoplasm, and translocates to the nucleus where it activates TCF/LEF transcription factors to promote the expression of genes involved in cell proliferation and survival [1]. In hepatocellular carcinoma, oncogenic lncRNAs such as SNHG5 promote tumor proliferation and CSC-like properties by modulating UPF1 and hyperactivating the Wnt/β-catenin pathway [1]. XAV-939 intervenes in this oncogenic cascade by inhibiting the Wnt/β-catenin pathway, thereby counteracting the downstream transcriptional activation of target genes and effectively neutralizing the CSC-promoting effects driven by upstream dysregulations [1].
4. Structure-Activity Relationship (SAR)
The provided literature focuses on the biological and molecular roles of the lncRNA/Wnt signaling axis in digestive system cancers and the functional utility of Wnt inhibitors. Consequently, specific chemical structure details and Structure-Activity Relationship (SAR) data for the compound XAV-939 are not discussed in the provided text [1]. Its characterization in the current context is strictly limited to its functional classification as a Wnt/β-catenin pathway inhibitor capable of disrupting cancer stem cell self-renewal [1].
5. Current Limitations
The primary limitation in the current research regarding XAV-939 and other Wnt/β-catenin pathway inhibitors is the heavy reliance on preclinical models. The interactions between the Wnt signaling pathway, lncRNAs, and targeted inhibitors have been extensively studied in *in vitro* cell lines and *in vivo* animal models; however, there is a significant lack of clinical validation [1]. The absence of direct validation in human patient samples leaves the clinical applicability, safety profile, and translational relevance of these findings uncertain [1]. Furthermore, tumor heterogeneity and molecular variability among patients present substantial challenges in ensuring consistent therapeutic responses to Wnt pathway inhibitors in a clinical setting [1].
6. Future Perspectives
To bridge the gap between preclinical success and clinical application, future research must prioritize comprehensive clinical investigations. It is essential to conduct studies utilizing human clinical samples to validate the therapeutic mechanisms of XAV-939 and its interaction with the Wnt/β-catenin pathway in cancer progression [1]. Furthermore, initiating well-designed clinical trials is critical to assess the safety, tolerability, and efficacy of XAV-939 in patients with digestive system tumors [1]. Undertaking multicenter studies to collect larger patient datasets will be vital to verify the generality of these mechanisms across diverse populations and to develop personalized, targeted treatment strategies based on individual molecular profiles [1].
